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Summary 
 
 Recent advances in the field of nanomaterials have given rise to several 
opportunities in biomedical research and clinical applications. These nanomaterials 
have been used for various applications, which include drug delivery, in vitro 
diagnostics, in vivo imaging, therapy and tissue engineering. At present, numerous 
organic/inorganic nanomaterials and devices are under investigation all across the 
globe. One such nanomaterial in its rising phase is “dendrimers”. Although this area 
has been known to the scientific world for almost last three decades, a lot remains 
unexplored. We have considered and studied natural amino acid derived, small 
generation peptide dendrimers as a platform for delivery of drugs and other materials.  
The main objective of this study was to prepare a library of small generation 
peptide dendrimers with various functionalities and to characterize them using 
conventional methods like size analysis, zeta potential, HPLC and ESI±MS along 
with new techniques available at hand such as Raman spectroscopy, SEM and live 
cell imaging. Further, we did preliminary experiments to see the uptake of dendrimers 
in HeLa and MCF-7 cells and study the toxicity effect of the dendrimers using MTT 
assay. Our results indicate that these small dendrimers (between 3-10 nm) being 
organic molecules are difficult to be characterized using Raman spectroscopy as was 
seen with the lack of specific bands. Furthermore, the MTT assay shows that these 
peptides are non-toxic even at concentrations of 200 µM.  
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1.1 NANOTECHNOLOGY AND NANOMATERIALS  
     
Today, nanotechnology is a commonly used buzzword not only in the diverse 
fields of science but in our day-to-day life, recently expanding in the area of drug 
delivery as well (Dosch 2001; Otto and de Villiers 2009). Multiple definitions have 
been coined to describe nanotechnology and nanoscience, which are often used 
interchangeably. One of the numerous ways to define nanoscience could be any 
activity aimed at understanding natural laws at a nanoscale level, while 
nanotechnology can be defined as the novel and practical applications of that 
scientific knowledge to change the world we reside in (Balzani 2005).  
Nanotechnology is often described as exploitation of materials with structural 
features and dimensions ranging between atoms and the molecule scale with the 
essential criteria that at least one of its dimensions is in nanometer length scale (≈ 100 
nm) (NNI 2007; Demming 2013). According to the website of US National Science 
Foundation (NSF), nanotechnology is defined as research and technology 
development at the atomic, molecular, or macromolecular level, in the length scale of 
approximately 1-100 nm range, to provide a fundamental understanding of 
phenomena and materials at the nanoscale and to create and use structures, devices 
and systems that have novel properties and functions because of their subcellular size 
(National Science Foundation 2000).  
Chapter 1. Introduction 
 2 
A lot of effort has been focused on nanotechnology, based on encouraging 
results obtained with materials or devices with nanoscale dimensions. 
Nanotechnologists plan to use these unique features of nanoscale material to address 
several problems in physics, medicine, as well as computers and electronics, energy, 
and aerospace. For example, 1) carbon nanofibers and carbon black nanoparticles are 
most commonly used nanosize filling materials in textile industries. They can 
effectively increase the tensile strength, abrasion resistance and toughness of 
composite fibers (Harholdt 2003; Gulrajani and Gupta 2011); 2) sunscreen containing 
titanium oxide (TiO2) nanoparticles, shows long-term stability when compared with 
traditional chemical ultraviolet (UV) protection approach via production of  less 
reactive oxygen species (ROS) upon UV illumination (Lewicka, Yu et al. 2013). 
Furthermore, nanotechnology has also covered areas such as energy saving; similarly, 
a strong reduction of energy consumption for illumination could be achieved by the 
use of light-emitting diodes (LEDs) (Gouveia-Neto, Da Silva et al. 2012). Another 
application area includes environment, which makes use of nanoporous membranes 
for water purification (Gondal, Dastageer et al. 2009),  magnetic nanoparticles for 
waste-water treatment and removal of heavy metal contaminants or toxic substances 
(Xu, Zeng et al. 2012). Additionally, nanoscale integrated circuits (Haselman and 
Hauck 2010) and electronic devices (Yu and Meyyappan 2006; Bogue 2010) in the 
field of information and communication play a vital role in the assembly of high-
speed central processing units (CPUs) and larger-capacity memory storage systems 
while reducing their costs (El-Hami, Hara et al. 2001). Although relatively new, a 
major focus of nanotechnology is diverted in the area of medicine. The concept of 
employing nanotechnology in biomedical research and clinical practice is best known 
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as nanomedicine. The next section discusses the use of nanotechnology in the field of 
nanomedicine.  
1.1.1 NANOTECHNOLOGY IN NANOMEDICINE     
Nanomedicine is an evolving field with a huge potential to cast a major impact 
on human health. Currently, biomedical and pharmaceutical fields have been using 
nanomaterials for distinctive applications, like tissue engineering, vaccination, 
chemotherapy, targeted drug delivery, cell therapy, gene therapy, protein/peptide 
delivery, molecular imaging and diagnostics (Table 1) (Goldberg, Langer et al. 2007).  
Table 1. Nanomedicine in the 21st century. Taken from (Jain 2008) 
Nanodiagnostics:   
• Molecular diagnostic 
• Imaging with nanoparticle contrast materials 
• Nanobiosensors 
Nanopharmaceuticals:  
• Nanotechnology-based drugs 
• Targeted drug delivery to site of action 
• Drug delivery from implanted nanopumps and nanocoated stents 
Reconstructive surgery:  
• Tissue engineering with nanobiotechnology scaffolds 
• Implantation of rejection-resistant artificial tissues and organs 
Nanorobotics:   
• Vascular surgery by nanorobots introduced into the vascular system  
• Remote controlled nanorobots for detection and destruction of cancer 
Nanosurgery:  
• Nanosensors implanted in catheters to provide real-time data during surgery  
• Nanolazer surgery 
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The benefits offered by nanoscale medical agents or devices is that they are 
often less invasive and can be implanted within the body which improves their patient 
compliance since they need not be administered frequently; additionally, their 
characteristic physicochemical or biological properties, enable them to be targeted to 
diseased sites (Farokhazad and Langer 2006). Their application to nanomedicine has 
attempted to exploit the unique properties of these nanomaterials: both in vitro and in 
vivo experiments took advantage from their size similar to that of many proteins and 
other biological structures (Sahoo, Parveen et al. 2007; Terlega and Latocha 2012). 
The most common nanotech platforms today include polymeric nanoparticles, 
nanoshells, micelles, liposomes, dendrimers, nucleic acid based nanoconstructs, 
engineered viral nanoparticles, magnetic nanoparticles, silicon oxide nanoparticles, 
and quantum dots (Ferrari 2005).  
One of most common applications of nanotech in nanomedicine is represented 
by the antimicrobial activity of nanomaterials for wound treatment (Nagy, Harrison et 
al. 2011; Pinto, Fernandes et al. 2012). Bandages infused with silver (Ag) 
nanoparticles accelerate wound healing (Keen, Desai et al. 2012). A topical 
application made up of nanoparticles containing nitric oxide (NO) and 
diethylenetriamine (DETA NONOate) that has direct antifungal activity, could 
significantly reduce the infection by releasing nitric oxide at the site of staph 
abscesses in case of burns (Blecher, Martinez et al. 2012; Macherla, Sanchez et al. 
2012).  
Another area of medicine making use of nano platform is “nanodiagnostics”, 
which uses nanobiotechnology in molecular diagnostics. This area seeks to develop 
diagnostics and imaging techniques, which will aid in quick identification of diseases 
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and precise location of cancer tumors. The current drive in developing techniques 
such as functional magnetic resonance imaging (MRI) is to enhance spatial resolution 
through contrast agents. One such most characterized system is represented by iron 
oxide (FeO) nanoparticles, used in conjugation with MRI for enhanced resolution. 
This system has been found to be significantly more sensitive for detection of prostate 
cancer lymph node metastasis as compared to conventional MRI (Barentsz, Fütterer et 
al. 2007; Hsieh, Liang et al. 2012). DNA pieces tethered with gold nanoparticles 
(AuNPs) can be used for detection of DNA sequences in biological samples (Gao, 
Sheng et al. 2011; Torres-Chavolla and Alocilja 2011). Quantum dots (QDs) are 
inorganic flourophores that offer an edge over conventional flourophore molecules. 
Due to high contrast and stable QD conjugates their visualization is superior in tumor 
sites, this further enables their integration with therapeutics (Oostendorp, Douma et al. 
2010; Pericleous, Gazouli et al. 2012). With the advent of stem cell therapy one of the 
limitations observed was the inability to precisely follow their fate within human 
body. This cannot be achieved with conventional fluorescence microscopy. 
Gadolinium-based MR contrast agents have shown promising properties for MRI cell 
tracking after the introduction of stem cells post transplantation (Hsieh, Liang et al. 
2012) .  
In addition, tissue engineering, whereby new tissues are reconstructed using 
artificially stimulated cells over a suitable nanomaterial-based scaffold, is another 
field being explored for the utilization of nanomedicine either to regrow or repair 
damaged tissues (Egli and Luginba Hl 2012; Hsieh, Liang et al. 2012; Ilie, Ilie et al. 
2012; Scott, Blackburn et al. 2013). For example, enhanced bone healing was 
observed with the delivery of osteogenic inducer, namely dexamethasone (DXM) 
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encapsulated in poly (amidoamine) dendrimer (PAMAM) nanoparticles (Oliveira, 
Kotobuki et al. 2010; Oliveira, Sousa et al. 2011).  
1.1.2 NANOTECHNOLOGY IN DRUG DELIVERY    
Drug delivery is an important aspect and plays a crucial role in drug 
therapeutics. One of the major reasons for the lack of efficacy of therapeutics is their 
poor delivery to the site of action. Nanocarriers (e.g., liposome, nanoparticle, QDs) 
(Figure 1) are often used to carry poorly soluble, unstable, or systemically toxic 
drugs. Several of the advantages offered by these nanocarriers include protection of 
drug from degradation within gastrointestinal (GIT) environment and enhanced oral 
bioavailability with increased blood circulation, which in turn controls the drug 
release. Additionally, low drug plasma fluctuation and minimized side effects are 
observed (Farokhzad and Langer 2009). Overall increased effectiveness, safety, 
patient adherence and reduced health care cost can be achieved with the effective use 
of nanocarriers. Some early studies reported the potential of nanoscale drug delivery 
systems and since then a myriad of these delivery systems have been documented 
(Lammers 2013).  
Within the family of nanomaterials for drug delivery, dendrimers have 
emerged as a new alternative and efficient tool for transporting and translocating 
therapeutic molecules inside the cells. Dendrimers can be used to deliver drugs, 
nucleic acids and other cargos to cells and organs. Peptide dendrimers employed in 
this thesis display low toxicity and are not immunogenic; hence they hold great 
potential in the field of nanobiotechnology and nanomedicine. 
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Figure 1. Timeline of nanotechnology based drug delivery. Adapted with permission from 
(Shi, Votruba et al. 2010) 
1.2 MAIN FEATURES OF DENDRIMERS 
 
Dendritic structures have emerged as a novel class of polymers. They were 
first reported by Vogtle et al. with nomenclature ‘cascade’ molecules. Development 
of this field led to large dendritic structures, which were subsequently renamed as 
‘dendrimers’ (Buhleier, Wehner et al. 1978; Tomalia 1994; Niederhafner, Šebestík et 
al. 2005). Dendrons and dendrimers are the most intensely investigated subset of 
dendritic polymers. The word dendrimer is derived from the Greek words dendri- 
(tree branch-like) and meros-(part of), and was coined by Tomalia et al. about 20 
years ago in the first research article on PAMAM dendrimers (Tomalia, Baker et al. 
1985). They are multi-branched, synthetic macromolecules possessing extremely low 
polydispersity, regular and high degree of branching, multivalency, nano-size, a 
globular architecture and a well-defined molecular weight. 
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1.2.1 DIFFERENT TYPES OF DENDRIMERS 
Dendrimers are classified on the basis of their composition and structure of the 
core, branches and surface groups and their substitution. They can be distinguished 
into the following classes, for example, PAMAM dendrimers (aka starburst 
dendrimers), poly(propylene imine) (PPI) dendrimers, polyester dendrimers, 
poly(propylene oxide)-polyglycerol dendrimers, porphyrin dendrimers with 
pyrimidine units, metallodendrimers, organometallic dendrimers, ferrocenyl 
dendrimers, sugar-containing carbosilane dendrimers, silicon-based dendrimers 
(carbosilane, polysilane, carbosilazane, siloxane and carbosiloxane), phosphorus 
dendrimers, peptide dendrimers (multiple antigen peptides; MAPs) and glycopeptide 
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f)  
      g)   
Figure 2. Different types of dendrimers: a) Poly-amidoamine dendrimer (PAMAM), b) 
Polypropylene imine dendrimer (PPI), c) Polyether dendrimer, d) Polyester dendrimer, 
e) Thiophosphate dendrimer, f) Carbosilane dendrimers and g) Poly-L-Lysine 
dendrimer. Source taken from: Wikipedia.  
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1.2.2  PHYSICOCHEMICAL PROPERTIES OF DENDRIMERS 
The basic properties of dendrimers are as follows (Sebestik, Niederhafner et al. 
2011): 
1. Nanometric dimensions similar to biomacromolecules (like proteins and 
DNAs). Their nanometric size offers improved delivery of drugs and 
controlled excretion of dendrimers from the body. 
2.  High numbers of functional groups at the surface of dendrimers are available 
for conjugation with targeting moieties, drugs, or biocompatible groups. Their 
conjugation influences various properties such as biodistribution, receptor-
mediated targeting, dose, or controlled release of drugs from the interior space.  
3. Low immunogenicity, possible to be achieved via conjugation of surface 
groups with polyethylene glycol (PEG).  
4. Encapsulation of drugs, metals, genes and/or probes in the interior 
hydrophobic space. 
5. Desired biocompatibility found with lower generation anionic or neutral polar 
terminal surface groups in contrast to higher generation neutral apolar and 
cationic surface groups which are often highly toxic. 
1.2.3 DENDRIMER FEATURES OF INTEREST TO NANOMEDICINE 
Opposite to traditional polymers, dendrimers have unique core-shell structures 
possessing three distinct parts (Figure 3), each of which can be modulated: 1) Core, 
which is the molecular information center from where size, shape, directionality, and 
multiplicity are expressed via the covalent connectivity to the outer shells. 2) Interior, 
within which one finds the branching amplification region, which defines the type and 
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volume of interior void space, which are then enclosed with the terminal groups as the 
dendrimer grows. The interior composition determines the extent and nature of guest-
host properties that are possible within a particular dendrimer family and generation. 
3) Surface (aka periphery), which consists of reactive or passive terminal groups that 
may perform several functions including being site for drug/antigen or antibody 
attachment (Meijer, Jansen et al. 1994; Chauhan, Svenson et al. 2007).  
 
Figure 3. Showing the structure of dendrimer and spaces where interaction between the 
dendrimer and drug molecule occurs. Modified from Chauhan, Svenson et al. 2007). 
 
Two different approaches are used to synthesize dendrimers: 1) the divergent 
method which starts from the central core and extends towards the surface (Tomalia, 
Dewald et al. 1984); 2) the convergent method which starts from the periphery of the 
dendrimer and progresses towards the core (Tomalia 2005; Svenson and Tomalia 
2012) or 3) a combination of both. Some of the commonly encountered types of 
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dendrimers in biological applications are based on PAMAM, polyamines, polyamides 
(polypeptides), poly (aryl ethers), polyesters and carbohydrates. 
1.2.4 DENDRIMER MATERIALS IN DRUG DELIVERY 
There is an immense need to deliver unaltered molecules using polymeric 
carriers and this has led to the exploration of dendrimers for evaluation as drug 
delivery vehicles (Gillies and Frechet 2005). In general, dendrimers could be 
functionalized via two different methods (Figure 4) for drug delivery: 1) Covalent 
attachment between the drug and the periphery of the dendrimer to form dendrimer 
prodrugs (which is either oxidation-labile or acid sensitive) and 2) non-covalent 
coordination of the drug to the outer functional groups of dendrimers. This interaction 
includes either hydrophobic interaction between the drug and dendrimer or ionic 
interaction. Furthermore, nanodevices such as carbon nanotube (CNT), nanorods or 
gold nanoparticles can adhere to dendrimers based on covalent or non-covalent 
functionalization (McCarroll, Baigude et al. 2010). Therapeutics with functional 
groups readily ligate to dendrimer via covalent bonding. It is advantageous when 
drugs cannot associate with dendrimers through physical interactions or stable 
interaction of drug is preferred to prevent untimely release of drugs with the chances 
to produce side effects. Modification using bioactive dendrimer has several fold 
benefits such as it might improve biocompatibility, enhance solubility and provide a 
mechanism for tissue- or cell-specific targeting (Liu, D. et al. 2012). 
 In recent years, several peptide-based dendrimers such as polylysine, 
have been reported and developed as promising vaccine, antiviral and antibacterial 
candidates with suitable surface modification (Figure 5) (Denkewalter, Kolc et al. 
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1984; Mignani, Kazzouli et al. 2013). Polyester dendrimers have been explored as an 
anticancer drug delivery system and in tissue engineering (De Jesus, Ihre et al. 2002; 
Grinstaff 2002). Furthermore, Duncan et al., reported that conjugating PAMAM 
dendrimers with cisplatin, a potent anticancer drug with poor solubility and non-
specific toxicity, resulted in lowered toxicity and improved water solubility (Duncan 
and Malik 1996). Similarly, epidermal growth factors (EGF) were targeted with a 
conjugate of boron atoms on cetuximab (monoclonal antibodies with specificity for 
EGF receptors) with [G5] PAMAM dendrimers. In vivo studies through post 
intratumoral injection suggests that the above conjugate resulted in 10-fold higher 
concentration in brain tumors than in normal brain tissue (Wu, Barth et al. 2004). 
Further, recently another class of dendrimers, namely poly (L-glutamic acid) based 
dendrimer conjugated with doxorubicin and targeting moiety biotin have been 
demonstrated as smart targeting drug delivery systems (Yuan, Luo et al. 2010). 
Another category of phosphorus dendrimers are speculated to be good candidate for 
the effective delivery of drugs as anti-HIV therapy as it was observed in case of [G4] 
phosphorus dendrimer and anti-HIV p24 siRNA (Liu, D. et al. 2012; Ferenc, 
Pedziwiatr-Werbicka et al. 2013).   
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Figure 4. Different types of dendrimer-therapeutic carrier association. In non-covalent 
association either there could be hydrophobic interaction between the drug and dendrimers or 
ionic binding. Additionally, there could be covalent attachment that could include degradable 
linkages (like cysteine containing disulfide bonds) and dendrimers can also be used to 
functionalize or enhance the solubility and biocompatibility of nanodevices either using 
covalent or non-covalent functionalization (e.g. CNT, nanorods or quantum dots). Modified 
from Liu, D et al., 2012.  
Additionally, they have a much higher surface functional group density when 
compared with conventional macromolecules which makes them even more suitable 
as drug delivery systems (Pettit, Griffiths et al. 2011). Due to their nanosize and 
multifunctional features, they have received considerable scientific interest. 
Biomedically, dendritic polymers have extensively been studied for drug/gene 
delivery, protein and peptides, designing protein resistant surfaces, fabricating 
diagnostic agent, and constructing biosensor devices (Cheng, Xu et al. 2007). 
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Figure 5. Main formulations and route of administration using dendrimers. Modified 
from Mignani, Kazzouli et al. 2013.  
1.2.5 DENDRIMERS BASED ON AMINO ACID AS BUILDING 
BLOCKS  
As mentioned above different types of dendrimers are currently used in the 
field of biomedical applications. However, one of the major drawbacks associated 
with classical dendrimers such as PAMAM and poly-(propylenemine) PPI is their 
toxic effect, which increases with increasing generation and cationic nature. 
Dendrimers contain amide linkages (e.g. the PAMAM class), but few are built from 
naturally occurring amino acids. Tam pioneered the synthesis and study of multiple 
antigen peptides (MAPs) (Sadler and Tam 2002; Tam, Lu et al. 2002). Interestingly, 
one of the earliest reports of a dendrimer, a patent by Denkewalter et al. 
(Denkewalter, Kole et al. 1984), reported the synthesis of lysine dendrimers. The 
basic idea consisted of using a simple scaffold of trifunctionalized lysine as a low 
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molecular weight synthetic carrier to which multiple copies of peptide antigen were 
bound.  Various potential advantages are associated with the use of these peptide-
based delivery vehicles. For instance, they are free of infectious material as opposed 
to the phages or viral vectors. They have the ability to reduce the sequence to the 
binding domain only and hence exclude risks of undesired effects due to side 
sequences. 
Arginine dendrimers have been designed and synthesized using the same 
approach used for polylysine MAPs (Derossi, Joliot et al. 1994; Vivès, Brodin et al. 
1997; Snyder and Dowdy 2004; Futaki 2005). These dendrimers consist of polylysine 
core, L-lysine branching units, and L-arginine surface groups. These arginine 
containing dendrimers have also been used in the design of molecules for the 
intracellular delivery of exogenous molecules into cells (Suzuki, Futaki et al. 2002). 
Several histidine-rich polymers and peptides with imidazole polar head have been 
reported to be efficient carriers to deliver nucleic acid including genes, mRNA and 
siRNA in vitro and in vivo (Chen, Zhang et al. 2001; Midoux, Pichon et al. 2009). 
1.2.6 DENDRIMER FUNCTIONALIZATION AND DELIVERY 
Dendrimer based on the functionalization at the terminal group can be 
positive, neutral or negative charged. The surface charge affects both the cytotoxicity 
of dendrimers and their delivery aspect. As mentioned in previous sections, 
hydrophobic drugs can be encapsulated within the dendrimer whereas hydrophilic 
drugs attach at the periphery of the dendrimers. Drug encapsulated in dendrimers are 
often released as a response to external stimuli. The drug released from the 
dendrimers is often achieved through the confirmation change triggered due to 
different pH and ionic strength of the medium. Positively charged polymers and 
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dendrimers have been complexed with nucleic acid such as DNA and siRNA (that are 
negatively charged and delivered into different cells). The negatively charged DNA 
complexes with positively charged dendrimers; due to branched structure and 
multivalency, there are additionally available positive charges on the surface that 
allow for their interaction with the negatively charged cell membrane. This interaction 
leads to their entry into the cells.   
The mechanism of drug release from the dendrimers can be represented 
depending on molecular conformation change with different pH and surface charge. 
In case of PAMAM and PPI dendrimers, molecules are globular and compact at high 
pH. At pH > 9, the surface terminal groups fold due to hydrogen bonding of the 
interior amide and/or tertiary amine with a primary amine creating a dense interior. 
Whereas, at lower pH (pH < 6.7), extended confirmation dictates due to the 
electrostatic repulsion between protonated tertiary amine in the interior. With 
carboxylic acid terminated dendrimers, at lower pH the dendrimer exhibits an 
extended confirmation due to electrostatic repulsion of protonated tertiary amines. 
However, at neutral pH (4.2 < pH < 6.7), the terminals of the dendrimer slightly fold 
due to the presence of attractive Coulombs’ interaction between terminal carboxyl 
groups (negatively charged) and the interior tertiary amines (positively charged). At 
high pH (pH > 6.7), the electrostatic repulsion between negatively charged surface 
carboxyl groups results in extended confirmation (Leisner and Imae 2003). 
Furthermore, the surface charge not only affects the drug release or their entry 
into the target cells, but also affects their toxic profiles. For example, among 
melamine-based dendrimers carrying amine, guanidine, carboxylate, sulfonate, 
phosphonate, or PEG on the periphery, positively charged dendrimers were found to 
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exhibit higher cytotoxicity in MTT assay compared to the anionic or PEG 
functionalized dendrimer. The reason behind higher toxicity seen with cationic 
dendrimer is due to the fact that they tend to destabilize cell membrane, induce cell 
lysis and determine interactions with the blood components (Tsai and Imae 2010).   
1.3 HYPOTHESIS AND OBJECTIVES  
 
In this project we hypothesize that amino acid based peptide dendrimers with 
different functionalities can be an efficient platform as non-viral vector able to be 
internalized by cells owing to their small size, their surface functionalization and/or 
charge and their non-toxic nature.  
In an attempt to prove our above hypothesis, we set forth the following specific 
objectives: 
1) To synthesize amino acid based peptide dendrimer library with different 
modifications. The first modification is to vary the number of amino acids on the 
terminal side and this generates either 4 or 8 amino group-containing dendrimers. 
The second modification includes dendrimers conjugated either in linear or 
branched fashion. The third modification includes either positive (due to –NH2) or 
negative (due to –COOH) terminal groups. The fourth modification is based on 
the change in amino acids (which included either lysine, arginine, proline or 
histidine). 
2) To purify linear and asymmetric dendrimer using preparative HPLC and 
characterize using and RP-HPLC and ESI±MS. 
3) To further characterize the dendrimers using techniques such as particle sizing, 
zeta potential, SEM and Raman spectroscopy. 
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4) To evaluate the effect of dendrimer uptake on HeLa cells to assess their cytotoxic 
effect using live cell imaging and MTT assay. 
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CHAPTER 2 




As discussed in chapter 1 this thesis primarily focuses on the natural amino 
acid derived small peptides, either linear or dendrimeric in sequence. In order to 
create a big library, peptide synthesized contained different amino acids such as 
glycine, lysine, proline, arginine and histidine respectively. Synthesizing linear and 
dendrimer peptides also introduced modification. Furthermore, different generation 
peptides were also synthesized such as 4 and 8 charges. Additional modification was 
done based on terminal group either ending as amino (—NH2) or carboxy (—COOH) 
or (—COCH3). —COCH3 group was attached at the terminus in linear peptides to 
avoid their folding.  
2.2 DENDRIMER SYNTHESIS 
 
Dendrimer synthesis involves divergent (Tomalia-type) or convergent 
(Frèchet-type) hierarchical assembly strategies that require the construction 
components as shown in Figure 6. Within each of these major approaches there may 
be variations in methodology for branch-cell construction or dendron construction.    
Dendrimer synthesis can be generally performed by two major strategies, 1) 
Divergent method and 2) Convergent method respectively. Hereby we will detail 
some of the main aspects of both the methods.  
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Figure 6. Hierarchical assembly scheme illustrating the options for constructing 
dendrimers by either divergent or convergent synthetic strategies. 
2.2.1 DIVERGENT METHOD 
Synthesis is initiated from a core site (Figure 7). In the divergent method, 
single monomeric molecules are then incorporated on the core in a radial, branch-
upon-branch motif. Every individual monolayer thus formed indicates a generation. 
The reactive monomer generally comprises of one reactive group and two or more 
unreactive/masked groups. Coupling the core with a monomer results in the formation 
of the 1st generation (G1) (Figure 7). By unmasking the two or more surface groups 
on the G1 dendrimer more reactive sites are exposed in readiness for the next 
monomer coupling. The advantages are as follows: 1) cheap reagents, 2) fast 
synthesis, 3) exponential growth and 4) possibility to prepare large dendrimers. 
However, the disadvantages include: complicated purification due to contamination of 
desired product by thousands of deletion compounds with molecular weight, charge, 
polarity, hydrophilicity etc. very similar to the desired product. 
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Figure 7. Schematic of divergent synthesis of dendrimers 
 
2.2.2 CONVERGENT METHOD  
Dendrimers are built up in a similar fashion to the divergent approach however 
synthesis terminates at the core rather than the highly branched surface of the 
dendrimer. Here, two or more peripheral branch units are reacted with a single joining 
unit comprising of a distal protected site and two or more active sites. The resulting 
branched unit then had its distal sites joining unit (Figure 8). The associated 
advantages includes: 1) monodisperse, 2) capability of attaching different types of 
dendrons to one dendrimer, 3) easier purification and characterization of product. 
Both the strategies have their advantages and disadvantages and appropriate strategy 
of dendrimer synthesis depends mainly on designed structure and generation. 
  
Figure 8. Schematic of convergent synthesis of dendrimers. 
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2.3 SOLID PHASE PEPTIDE SYNTHESIS (SPPS) 
 
2.3.1 BACKGROUND         
Peptide synthesis is based upon the proper combination and manipulation of 
temporary and permanent protecting groups, as well as the choice of efficient 
coupling reagents for the controlled formation of the peptide. For dendrimers to be 
effective as vaccine delivery agents, their synthesis needs to be optimized to deliver 
homogenous end products. It is vital to know the precise composition of a 
manufactured product intended for in vivo use, not only for it is to be accepted into 
clinical trials; but also to allow structural modifications to optimize activity. 
Peptide dendrimers form the focus of thesis, and are formed by amino acids 
via amide/peptide bonds, in a sequential manner. Historically, such peptides were 
synthesized using solution phase synthesis, but the introduction of the relatively 
simple and cost-effective methods of solid-phase peptide synthesis (SPPS) by 
Merrifield led to the synthesis of innovative peptides more efficiently. R.B. Merrifield 
in 1962 was the first to report the use of SPPS and in 1963 he published his work 
outlining the “synthesis of a Tetrapeptide” which he called the classical approach to 
preparing biologically active peptides (Merrifield 1963). However, the original SPPS 
approach was not suitable for longer peptides and did not push the reactions to 
completion given that unprotected amino acids were employed. Additional chemical 
problems, limitations in available purification procedures, and the absence of reliable 
analytical techniques to the solid phase led to many failures. Changes to the approach 
were introduced by Sheppard et al. (Sheppard 2003), who protected the amino acids 
with the acid-labile t-butoxycarbonyl (Boc), which enabled synthesis of longer 
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peptides in a highly efficient manner. Selective cleavage of the terminal Boc was 
required at every cycle of amino acid addition. This approach was confirmed by the 
synthesis of a nonapeptide bradykinin. The Boc strategy is also commonly known as 
the ‘Merrifield technique’. The disadvantages of the Boc strategy include a lack of 
orthogonal protecting groups and the necessity to use strong acids (e.g. TFA) for 
removal of Boc.  
An alternative approach was then developed by Carpino (Carpino and Han 
1972); who introduced a base-labile fluorenylmethoxycarbonyl (Fmoc) protecting 
group (Figure 9). This provided a combination of temporary and permanent 
protecting groups cleavable under milder-conditions. It has proven both efficient and 
versatile, providing stepwise and fragment assembly procedures, analytical and 
monitoring techniques, and solutions to some of the previously limiting chemical 
problems. It encouraged the development of continuous flow methods and the 
construction of sophisticated automatic peptide synthesizing equipment with 
analytical feedback control. It has been applied to the synthesis of modified peptides 
including phosphorylated and glycosylated derivatives, to the multiple synthesis of 
peptides, and in combinatorial techniques, and generally offers promise as the method 
of choice of the synthesis of peptides. Fmoc-based SPPS has since been optimized 
and is a versatile technique for sequential addition of amino acids to an insoluble solid 
support, and is the approach used for constructing dendrimers employed in this 
project (Chan and White 2000).   
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2.3.2 THE SOLID PHASE PRINCIPLE 
Construction of a peptide chain on an insoluble solid support has obvious benefits 
such as: 
1) Separation of the intermediate peptides from soluble reagents solvents can be 
effected simply by filtration and washing consequently savings time and 
labour over the corresponding operations in solution synthesis. 
2)  Ease of automation. 
3)  Excess reagents can be employed to help drive the reactions to completion. 
4) Minimum physical losses as the peptide remains attached to the support 
throughout the synthesis. 
However, certain limitations are unavoidable such as: 
1) Contamination of the product either due to incomplete reactions, side 
reactions or impure reagents. 
2) Difficult purification of the products due to the similar nature of impurities 
and the desired peptide. 
3) General analytical techniques employed for following the progress of 
reactions in solution and so the presence of residual amines is relied on 
simple qualitative color test. 
The principles of solid phase synthesis are depicted in Figure 9. The C-
terminal amino acid residue of the target peptide is attached to an insoluble support 
via its carboxyl (–COOH) group. Any functional group in amino acid side chains 
must be masked with permanent protecting groups that are not affected by the 
reactions condition employed during peptide chain assembly. The temporary 
protecting group masking the α-amino group during the initial resin loading is 
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removed. An excess of the second amino acid is introduced, with the –COOH group 
of this amino acid being activated for amide bond formation through generation of an 
activated ester or by reaction with a coupling reagent. After coupling, excess reagents 
are removed by washing and the protecting group removed from the N-terminus of 
the dipeptide, prior to addition of the third amino acid residue. This process is 
repeated until the desired peptide sequence is assembled. In a final step, the peptide is 
released from the support and the side-chain protecting groups removed. Generally, 
side-chain protecting groups and resin linkage are chosen such that protecting groups 
are removed and the assembled peptide released under the same conditions. 
 
Figure 9. Schematic representation of solid phase peptide synthesis principle. Adapted 
from (Chan and White 2000). X = Temporary amino protecting group; Y = Permanent side-
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2.3.3 FMOC/TBU SPPS 
Unlike the Merrifield approach which utilizes a regime of graduated acidolysis 
selectivity to achieve selectivity in the removal of temporary and permanent 
protection, the Fmoc/tBu method is based on an orthogonal protecting group strategy, 
using the base-labile N-Fmoc group for protection of the α–NH2 group and acid-labile 
side-chain protecting groups and resin linkage reagents. Since removal of temporary 
and permanent protection is effected by completely different chemical mechanisms, 
side-chain protecting groups and linkage agents can be employed that are removed 
under considerably milder conditions than those used in the Merrifield method. In 
practice, t-butyl and trityl-based side-chain protection and alkoxybenzyl-based linkers 
are used as they can be removed with TFA. This reagent is an excellent solvent for 
peptides and being volatile is readily removed by evaporation. Indeed, it is this 
inconvenience of the cleavage reaction and the ease with which the method can be 
adapted to multiple peptide synthesis that are undoubtedly the reasons for the 
popularity of the Fmoc/tBu approach. 
2.4 MATERIAL AND METHODS 
 
2.4.1 MATERIALS 
Rink amide resin (200-400 mesh) were purchased from NovaBiochem 
(Australia). Fmoc amino acids were either purchased from NovaBiochem (Australia) 
and/or Mimetopes (Australia) respectively. The solvent employed throughout the 
synthesis was peptide grade anhydrous N,N- dimethylformamide (DMF), 
Dichloromethane (DCM), Diisopropylcarbodiimide (DIPC), Dimethylaminopyridine 
(DMAP), 1,8-Diazabicycloundec-7-ene (DBU), N,N-Diisopropylethylamine 
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(DIPEA), Triethylamine (TEA), O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate (HBTU), piperidine, diethyl ether and Trifluoroacetic acid 
(TFA), Triisopropylsilane (TIPS) were purchased from Sigma-Aldrich® (Australia).  
2.4.2 METHODS AND INSTRUMENTATION 
2.4.2.1   ANALYTICAL HPLC 
 
Analytical RP-HPLC was performed using a Agilent (Japan) HPLC system 
(system controller-CBM-20A, pump A- LC-10AD, autosampler ‒ SL-10AXL, a 
variable wavelength UV/vis detector ‒ SPD-10A, degasser- DGU20 As Prominence) 
with a C4 column (GraceVydac; particle size: 5 µm pore size, Id = 4.6 mm x 250 mm, 
pore size: 300 Å) and mobile phase comprised Solvent A (0.02% HFBA(aq)) (Mutalik, 
Hewavitharana et al. 2009) and Solvent B (90% CH3CN(aq)). The solvents were 
filtered with a 0.45 µm filter following preparation. Analysis of each purified 
asymmetric dendrimer was undertaken in gradient mode at a flow rate of 1ml/min, 
using the following conditions: 100% A (0-20 min), then to 100% B linearly over 10 
min. Injection volume was 40 µL and detection wavelength was 218 nm. 
2.4.2.2    PREPARATIVE HPLC 
 
The coupling efficiency of each amino acid was monitored by a 
spectrophotometer (Varian C50 UV-Vis instrument). Purification of asymmetric 
dendrimers was performed by reverse-phase high performance liquid chromatography 
(RP-HPLC). Preparative RP-HPLC was performed on a Waters (USA) HPLC system 
(Model 600 controller, 2996 photodiode array detector, Elite Altech degassing system 
and MassLynx™ software) with a C4 column (GraceVydac; particle size: 10 µm pore 
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size; Id = 22 mm x 250 mm). Dendrimers were injected (∼100 mg/batch) using a flow 
rate of 10 ml/min; run time: 35 min, isocratic conditions (100% A) and purified with 
the mobile phase comprising solvent A (100% H2O), solvent B (90% CH3CN(aq)). 
Fractions were collected up to 20 min. 
2.4.2.3   LIQUID CHROMATOGRAPHY-MASS SPECTROSCOPY 
 
Liquid chromatography-mass spectroscopy (LC-MS) was performed using an 
Applied Biosystems/MDS Sciex Q-TRAP LC/MS/MS system (Life technologies, 
Australia). For ESI±MS, each dendrimer was dissolved in 50% CH3CN(aq) to 1 mg/ml 
and observed for the molecular ion. 
2.4.3 IDENTIFICATION TESTS  
2.4.3.1   AMINE GROUP QUANTIFICATION – NINHYRDIN TEST (KAISER 
TEST) 
 
A quantitative ninhydrin color test devised to detect the presence of free 
amines by spectrophotometry was employed (Kaiser, Colescott et al. 1970; Sarin, 
Kent et al. 1981). The reagents included:   
Reagent 1- 5% Ninhydrin in ethanol (w/v) 
Reagent 2- 80% Phenol in ethanol (w/v) 
Reagent 3- KCN in pyridine (2ml; 0.001M KCN in 98 ml pyridine)  
The ninhydrin test was performed using ∼1 mg resin sample, filters washed with DMF 
and dried under vacuum. To this add dried resin in a test tube, 2 drops of Reagent 1 (∼ 
50 µL), 4 drops of Reagent 2 (∼ 100 µL) and 2 drops of Reagent 3 (∼ 50 µL) were 
added. To another test tube only the reagents were added (blank). The test tubes were 
placed in a heating block for 5 min pre-adjusted to 100°C. After this time both the test 
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tubes were removed and 2.8 ml of 60% ethanol(aq) added to each test tube. The 
absorbance of the resin sample was read against the blank at 570 nm. Below are the 
formula’s used to calculate the free amino group after deprotection. 
𝑵𝒊𝒏𝒉𝒚𝒅𝒓𝒊𝒏 𝒗𝒂𝒍𝒖𝒆 (𝑵𝑽) = 𝑨𝟓𝟕𝟎𝒙 𝑽𝒎𝒍
έ𝟓𝟕𝟎
�
𝑨𝟓𝟕𝟎 𝐱 𝑽𝒎𝒍 έ𝟓𝟕𝟎 𝐱 𝑾𝒎𝒈�𝐱 𝟏𝟎𝟔 
 
Where: 
Extinction coefficient (έ570) is the molar absorbance of free amine groups (1.5 x 104 
M-1 cm-1) (REF), A570 is absorbance reading at 570 nm, W is mass of the resin and  
V is the volume of the sample. 
The coupling efficiency was calculated as a % as follows: % 𝒄𝒐𝒖𝒑𝒍𝒊𝒏𝒈 𝒆𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚 = 𝟏 − � 𝐍𝐕 𝐱 𝟏𝟎𝟎
𝒔𝒖𝒃𝒔𝒕𝒊𝒕𝒖𝒕𝒊𝒐𝒏 𝒗𝒂𝒍𝒖𝒆 � 
 
Substitution value (SV) expressed in µmole/g. 
The SV values for the subsequent couplings were calculated as follows: 
𝑺𝑽𝟏 = 𝑺𝑽[ 𝟏 + (𝑺𝑽 𝐱 𝟏𝟎𝟑𝐱 𝑴𝑾 𝒐𝒇 𝒇𝒊𝒓𝒔𝒕 𝒂𝒎𝒊𝒏𝒐 𝒂𝒄𝒊𝒅)] 𝐱 𝟏𝟎𝟑 
 
The MW of the first amino acid is calculated by first subtracting 18 amu i.e. MW of 
H2O liberated at each amino acid coupling step. 
2.4.3.2   ESTIMATION OF COUPLING TO PROLINE – ISATIN TEST 
 
A qualitative color test devised for determination of coupling to prolyl 
residues was employed (Kaiser, Bossinger et al. 1980). The test was performed using 
∼1 mg resin sample, filters washed with DMF and dried under vaccum. To this dried 
resin in a test tube, add 5 drops of Isatin reagent solution and 2 drops of 10% acetic 
acid. The test tube was placed in heating block pre-adjusted to 100°C for 5 mins 
followed by washing with acetone. Filter the beads and examine against a white 
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background. No color change or yellow color indicates negative test. While grey 
green or blue color indicates need for recoupling.   
2.4.4 ASYMMETRIC DENDRIMER SYNTHESIS AND OFF-RESIN 
CLEAVAGE    
Linear and asymmetric dendrimers were synthesized on a 0.50 or 1.00 mmol 
scale using Fmoc SPPS (Chan and White 2000). Rink amide resin (0.79 mmol/g 
loading capacity) was swollen in DMF in a sintered glass vessel for 60 min followed 
by Fmoc deprotection with 20% v/v piperidine in DMF (2 x 8 min washes). All amino 
acids were pre-activated prior to coupling using HBTU (0.5M in DMF) and DIPEA. 
Each coupling was monitored for ninhydrin values of ≥ 99% using a quantitative 
color test devised to detect the presence of free amino groups by spectrophotometry 
(Sarin, Kent et al. 1981), the Fmoc group was then deprotected as outlined above in 
DMF. The Rink amide resin and Fmoc-protected amino acids covalently attached in 
sequence to deliver the target dendrimer. In order to synthesize a negatively charged 
dendrimer, after the last amino acid coupling 50 molar excess of glutaric anhydride 
and DIPEA (50:50) were mixed. Once the desired dendrimer was synthesized, it was 
cleaved off-resin under acid conditions with TFA (TFA/TIPS/H2O – 90:2.5:2.5). This 
also cleaves the Pbf group on the dendrimers. The peptide was then filtered, TFA 
evaporated from solution, azeotroped with toluene/AcN and then triturated with cold 
diethyl ether. All dendrimers were then subjected to purification and analysis as 
mentioned in section 2.5.2 and 2.5.3. Table 2 below presents the list of synthesized 
linear and branched dendrimers.  
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Table 2. List of the peptide and dendrimer library prepared 




[M + H]+ 
4LL 4+ Linear L-Lys Gly-(Lys)3-Lys-NH-COCH3 C28H56N10O6 628.44 629.80 
4LLA 4+ Linear L-Lys (acid) Gly-(Lys)3-Lys-NH-CO-(CH2)3 -COOH C31H60N10O8 700.46 701.80 
4LA 4+ Linear Arg Gly-(Arg)3-Arg-NH-COCH3 C28H56N18O6 740.86 741.80 
4LAA 4+ Linear Arg (acid) Gly-(Arg)3-Arg-NH-CO-CH2-CH2-CH2-COOH C31H60N18O6 812.92 813.60 
4DL 4+ Lysine dendrimer Gly-Lys-(Lys)2-NH2 C20H42N2O4 458.60 459.40 
4DA 4+ Arginine dendrimer Gly-Lys-(Arg)2-NH2 C20H42N12O4 514.63 515.80 
4DH 4+ Histidine dendrimer Gly-Lys-(His)2-NH2 C20H31N9O5 476.53 477.30 
4DP 4+ Proline dendrimer Gly-Pro-Lys-(Arg)2-NH2 C25H49N13O5 611.74 612.70 
4DLA 4- Lysine dendrimer Gly-Lys-(Lys)2-(NH-CO-CH2-CH2-CH2-COOH)2 
C40H66N8O16 915.00 915.70 
8LL 8+ Linear L-Lys Gly-(Lys)7-Lys-NH-COCH3 C52H104N18O10 1141.50 1142.00 
8LLA 8+ Linear L-Lys (acid) Gly-(Lys)7-Lys-NH-CO-CH2-CH2-CH2-COOH C54H106N18O12 1199.53 1199.80 
8LA 8+ Linear Arg Gly-(Arg)7-Arg-NH-COCH3 C52H104N34O10 1364.60 1365.70 
8LAA 8+ Linear Arg (acid) Gly-(Arg)7-Arg-NH-CO-CH2-CH2-CH2-COOH C55H108N34O12 1437.67 1437.70 
8DP 8+ Proline dendrimer Gly-Pro-Lys-(Lys)2-(Arg)4-NH2 C49H97N25O9 1180.46 1181.30 
8DA 8+ Arginine dendrimer Gly-Lys-(Lys)2-(Arg)4-NH2 C44H90N24O8 1083.34 1084.10 
8DL 8+ Lysine dendrimer Gly-Lys-(Lys)2-(Lys)4-NH2 C44H90N16O8 971.29 971.60 
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0XYZ  where,      
0 = number of amino group or acid groups at the terminus (4 or 8) 
X = dendrimer (D) or linear (L) 
Y = terminal amino acid [Glycine (Gly), Lysine (Lys), Arginine (Arg), Proline (Pro)] 
Z = acid (A) 
 
 2.4.5 SYNTHESIS PROTOCOL FOR AMINO ACID BASED 
PEPTIDES 
2.4.5.1    Synthesis of 4+ Linear Lysine [4+ COCH3-(Lys)3-Lys-Gly-NH2]  (4LL) 
Protocol                 Time 
 
1. Resin (0.50 mmol) swelled in DMF (soak resin until submerged)        60 min 
2. Drained and incubated resin with 20% v/v piperidine in DMF & agitate (2 x 8 min) 
3. Washed DMF and then drained under vaccum                                      8-10 times 
4. Amino acid coupling (steps 4-9) 
a. Fmoc-Gly-OH (1.28 mmol, 380 mg in DMF) 
Add activation reagents 
i. HBTU (1.28 mmol, 2.5 mL; 4 eq w.r.t. original resin loading) 
ii. DIPEA 1.28 mmol, 225 µL; 4 eq w.r.t. original resin loading) 
5. Ninhydrin test          
6. Repeated step 3                                                                                        8-10 times 
7. Incubated resin with 20% v/v piperidine in DMF and agitate                 2 x 8 min 
8. Repeated step 3                                                                                        8-10 times 
9. Repeated step 4-8 with  
b. Fmoc-Lys(Boc)-OH (0.96 mmol, 468 mg) 
10. Washed with DCM and drained                                                           5-6 times 
11. Incubated resin with 20% v/v piperidine in DMF and agitated            2 x 8 min 
12. Ninhydrin test  
13. Washed with DMF, IPA and final wash with DMF and drained         5-6 times  
14. Excess of acetic anhydride and DIPEA (50 molar each w.r.t. to resin loading) 30 min  
15. Ninhydrin test  
16. Washed with DMF, IPA and final wash with DMF and drained         5-6 times  
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17. Washed with DCM and drained                                                       5-6 times 
18. Resin dried in-vacuo                  14-20 h 
19. TFA cleavage off-resin                 180 min 
a. TFA/TIPS/H2O – 95:2.5:2.5 (10 mL) 
20. Filtered solution  
21. Evaporated TFA in Rotavap           30-60 min 
22. Azeotroped with acetonitrile and toulene         3 x 15 mL 
23. Triturated with cold diethyl ether                               5 x 10 mL 
24. Dissolved residue in water and lyophilized  
25. Crude product after lyophilization was analysed by ESI±MS and purified by 
preparative RP-HPLC 
26. Reanalysed by ESI±MS and analytical RP-HPLC, with pure fractions pooled and 
lyophilized  
The yield calculated for all dendrimers were based on a 100 mg (crude) batch prior to 
purification by RP-HPLC. 







































Figure 10. Structure of 4+ Linear lysine: [4+ COCH3-(Lys)3-Lys-Gly-NH2] (4LL) 
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2.4.5.2    Synthesis of 4+ Linear Lysine (acid) [4+ COOH-(CH2)3-CONH-(Lys)3-
Lys-Gly-NH2] (4LLA) 
Protocol             
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.20 mmol, 357 mg in DMF) 
9. Repeated amino acid coupling with:  
a.  Fmoc-Lys(Boc)-OH (1.2 mmol, 562 mg) 
14. Excess of glutaric anhydride and DIPEA (50 molar each w.r.t. to resin loading) 
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2.4.5.3    Synthesis of 4+ Linear Arginine [4+ CH3CO-(Arg)3-Arg-Gly-NH2] (4LA) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (0.9 mmol, 267 mg in DMF) 
9. Repeated amino acid coupling with:  
a. Fmoc-Arg(Pbf)-OH (0.9 mmol, 584 mg) 
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2.4.5.4    Synthesis of 4+ Linear Arginine (acid) [4+ COOH-(CH2)3-(Arg)4-Gly-
NH2] (4LAA)  
Protocol             
 
All steps (1-13) are as described for Dendrimer 2 above except the quantity and 
sequential addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.77 mmol, 526 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Arg(Pbf)-OH (1.77 mmol, 1.15 g) 
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2.4.5.5    Synthesis of 4+ Lysine dendrimer [4+ (Lys)2-Lys-Gly-NH2] (4DL) 
Protocol             
 
All steps (1-13) are as described for 4LLA above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.18 mmol, 350 mg in DMF)    
9. Repeated amino acid coupling with:  
a. Fmoc-Lys(Fmoc)-OH (1.18 mmol, 553 mg) 
b. Fmoc-Lys(Fmoc)-OH (2.37 mmol, 1.11 g) 
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2.4.5.6    Synthesis of 4+ Arginine dendrimer [4+ (Arg)2-Lys-Gly-NH2] (4DA) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.56 mmol, 463 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Lys(Fmoc)-OH (1.17 mmol, 691 mg) 
b. Fmoc-Arg(Pbf)-OH (2.34 mmol, 1.52 g) 
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2.4.5.7    Synthesis of 4+ Histidine dendrimer [4+ (His)2-Lys-Gly-NH2] (4DH) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.8 mmol, 535 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Lys(Fmoc)-OH (1.8 mmol, 1.06 g) 
b. Fmoc-His-OH (3.6 mmol, 2.23 g) 
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2.4.5.8    Synthesis of 4+ Proline dendrimer [4+ (Arg)2-Lys-Pro-Gly-NH2] (4DP) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.2 mmol, 357 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Pro-OH (1.2 mmol, 404 mg) 
b. Fmoc-Lys(Fmoc)-OH (1.2 mmol, 709 mg) 
c. Fmoc-Arg(Pbf)-OH (2.4 mmol, 1.56 g) 
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2.4.5.9    Synthesis of 4- Lysine dendrimer [4- (COOH-(CH2)2-CONH-Lys)2-Lys-
Gly-NH2] (4DL)   
Protocol             
 
All steps (1-13) are as described for 4LLA above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.65 mmol, 490 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Lys(Fmoc)-OH (1.65 mmol, 975 mg) 
b. Fmoc-Lys(Fmoc)-OH (3.3 mmol, 1.95 g) 
ESI±MS m/z calculated for (C40H66N8O16): 914.46; found 915.70 [M + H]+ 
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2.4.5.10   Synthesis of 8+ Linear Lysine [8+ COCH3-NH-Lys-(Lys)7-Gly-NH2] 
(8LL) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (0.6 mmol, 178 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Lys(Boc)-OH (0.6 mmol, 281 mg) 
ESI±MS m/z calculated for (C52H104N18O10): 1141.50; found 1142.00 [M + H]+ 
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2.4.5.11   Synthesis of 8+ Linear Lysine (acid) [8+ COOH-(CH2)3-CONH-Lys-
(Lys)7-Gly-NH2]  (8DLA) 
Protocol             
 
All steps (1-13) are as described for 4LLA above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.2 mmol, 357 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Lys(Boc)-OH (1.2 mmol, 562 mg) 
ESI±MS m/z calculated for (C56H110N18O12): 1227.59; found 1228.10 [M + H]+ 
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2.4.5.12   Synthesis of 8+ Linear Arginine [8+ COCH3-Arg-(Arg)7-Gly-NH2] (8LA) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.5 mmol, 227 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Arg(Pbf)-OH (1.5 mmol, 497 mg) 
ESI±MS m/z calculated for (C52H104N34O10): 1365.60; found 1365.90 [M + H]+ 
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2.4.5.13   Synthesis of 8+ Linear Arginine (acid) [8+ COOH-(CH2)3-CONH-Arg-
(Arg)7-Gly-NH2] (8LAA) 
Protocol             
 
All steps (1-13) are as described for 4LLA above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.5 mmol, 227 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Arg(Pbf)-OH (1.5 mmol, 497 mg) 
ESI±MS m/z calculated for (C55H108N34O12): 1437.67; found 1437.70 [M + H]+ 
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2.4.5.14   Synthesis of 8+ Proline dendrimer [8+ (Arg)4-(Lys)2-Lys-Pro-Gly-NH2] 
(8DP) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.77 mmol, 526 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Pro-OH (1.77 mmol, 597 mg) 
b. Fmoc-Lys(Fmoc)-OH (1.77 mmol, 1.05 g) 
c. Fmoc-Lys(Fmoc)-OH (3.54 mmol, 2.1 g) 
d. Fmoc-Arg(Pbf)-OH (7.08 mmol, 4.6 g) 
ESI±MS m/z calculated for (C49H97N25O9): 1180.46; found 1181.1 [M + H]+ 
 
 
Figure 23. 8+ Proline [8+ (Arg)4-(Lys)2-Lys-Pro-Gly-NH2] (8DP) 
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2.4.5.15 Synthesis of 8+ Arginine dendrimer [8+ (Arg)4-(Lys)2-Lys-Gly-NH2] 
(8DA) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4.   Fmoc-Gly-OH (1.2 mmol, 357 mg in DMF) 
1. Repeated amino acid coupling with:  
a. Fmoc-Lys(Fmoc)-OH (1.2 mmol, 709 mg) 
b. Fmoc-Lys(Fmoc)-OH (2.4 mmol, 1.42 g) 
c. Fmoc-Arg(Pbf)-OH (4.8 mmol, 3.12 g) 
ESI±MS m/z calculated for (C44H90N24O8): 1083.34; found 1084.10 [M + H]+ 
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2.4.5.16    Synthesis of 8+ Lysine dendrimer [8+ (Lys)4-(Lys)2-Lys-Gly-NH2] (8DL) 
Protocol             
 
All steps (1-13) are as described for 4LL above except the quantity and sequential 
addition of each amino acid, which are as follows: 
4. Fmoc-Gly-OH (1.77 mmol, 526 mg in DMF)  
9. Repeated amino acid coupling with:  
a. Fmoc-Lys(Fmoc)-OH (1.77 mmol, 1.05 g) 
b. Fmoc-Lys(Fmoc)-OH (3.54 mmol, 2.09 g) 
c. Fmoc-Lys(Fmoc)-OH (7.08 mmol, 4.18 g) 
ESI±MS m/z calculated for (C44H90N16O8): 971.29; found 972.18 [M + H]+ 
 
Figure 25. Structure of 8+ Lysine [8+ (Lys)4-(Lys)2-Lys-Gly-NH2] (8DL) 
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2.5 RESULTS AND DISCUSSION 
2.5.1 AMINO ACID BASED LINEAR AND ASYMMETRIC 
DENDRIMER SYNTHESIS 
Linear and asymmetric dendrimers with 4 or 8 terminal amines or acids were 
constructed with different amino acids (such as Lys, Arg, His and Pro respectively) 
using Fmoc SPPS. For synthesis of various peptide systems, excess coupling reagents 
and amino acids were used, most commonly 3-fold excess of amino acid and coupling 
reagents, this being relative to the initial resin loading. Using a ninhydrin assay, the 
coupling efficiency of each amino acid was assessed as compete when it reached ≥ 
99%. Those that did not reach that coupling efficiency were agitated with reactants or 
heated in oven at 40°C to improve their reaction kinetics and further assessed using 
ninhydrin assay at intervals of 1 h until ≥ 99% was reached. In some cases, where 
coupling failed to complete after an additional 1 h (i.e. coupling < 97%, as determined 
by ninhydrin assay), the resin was washed with DMF and repeat coupling was 
performed. Here, 1-2 equivalents of activated amino acids were again added to the 
resin mixture without deprotecting the amino acid coupled to the resin. In other cases, 
where the coupling efficiency was nearing completion e.g. > 97-98%, 2 eq of DIPEA 
were added and the resin mixture allowed to rotate for an additional 1 h. In case of 
synthesis of 8 charge peptide synthesis, where coupling was found lower than 
required, acetic anhydride was used to cap the free amino groups to avoid formation 
of deletion products, which have deleterious effects on yield and purification. After 
cleavage off-resin and work up, the products were subjected to characterization.   
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2.5.2 AMINO ACID BASED LINEAR AND ASYMMETRIC 
DENDRIMER PURIFICATION  
Following purification with preparative RP-HPLC, all peptide-based systems 
were obtained in moderate-high yields ranging between 60-85%. When fractions were 
analyzed by analytical RP-HPLC, both single peaks and shoulder/multiple peaks were 
observed. Fractions that showed shoulder/ multiple peaks likely contained minor 
impurities were therefore pooled along with the crude dendrimer to avoid presenting 
impurities into the final product. Only fractions that showed a single peak an example 
chromatogram) by RP-HPLC were deemed to be pure and were pooled and 
lyophilized. The highly pure pooled-lyophilized samples were re-analyzed by 
analytical RP-HPLC, confirming single peak purity (Mutalik, Hewavitharana et al. 
2009).  
2.5.3 AMINO ACID BASED LINEAR AND ASYMMETRIC 
DENDRIMER CHARACTERIZATION  
The aim of the work described was to synthesize and fully characterize a panel 
of low-generation linear and asymmetric dendrimers. The design of these dendrimers 
permits conjugation to a non-targeted site while enabling conjugation with the model 
peptide. With the appropriate building blocks in place, synthesis of linear and 
asymmetric dendrimers via SPPS was undertaken. The molecular ion peak of each 
peptide system was confirmed by ESI±MS. Example ESI±MS spectra and RP-HPLC 
graph are shown below (Figure 26 and 27).  
 




Figure 26. ESI±MS of 4+Arginine peptide ([M + H]+ = 515.8; calculated mass = 514.63) 
 
Figure 27. RP-HPLC graph of 4+ Arginine peptide. Retention time (RT) = 3.16 min  
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ESI±MS and RP-HPLC were used to confirm synthesis of the linear and 
asymmetric dendrimers. ChemBioDrawTM structures of each system were used as an 
aid to confirm their molecular weight and also assist in determining the most likely 
fragments for interpretation of ESI±MS spectra. Analytical RP-HPLC confirmed the 
final purity of each system (with a single peak taken as evidence of purity). In 
conclusion, a panel of linear and asymmetric dendrimers was successfully synthesized 
and RP-HPLC and ESI±MS confirmed the structure of each. 
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CHAPTER 3  




Dendrimers synthesized over years have been characterized making use of 
various methods that includes HPLC, ESI±MS, differential light scattering (DLS), 
scanning electron microscopy (SEM), transmission electron microscopy (TEM), 
differential scanning calorimeter (DSC) etc. In this chapter we use several of the 
above and Raman technique to get an in-depth knowledge of amino acid based 
peptide dendrimers.  
3.2 MATERIAL AND METHODS 
3.2.1 MATERIAL 
4+ linear lysine dendrimer (4LL), 4+ lysine dendrimer (4DL), 4+ arginine 
dendrimer (4DR), 8+ lysine dendrimer (8DL), 8+ proline dendrimer (8DP), were 
synthesized as described in chapter 2. Human cervical epithelial cells (HeLa) were 
courtesy from Dr. Ho Han Kiat lab (NUS). MCF-7 cells Dulbecco’s modified Eagle’s 
medium (DMEM) and fetal bovine serum (FBS), dimethylsulfoxide (DMSO), 
phosphate buffer saline (PBS), were purchased from Invitrogen. HEPES was procured 
from Sigma-Aldrich Inc. (Singapore).  
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3.2.2 METHODS 
3.2.2.1   DYNAMIC LIGHT SCATTERING (DLS) 
A Malvern Zetasizer Nano ZS instrument (Southborough, MA) with back 
scattering detector (173°, 633 nm laser wavelength) was used for measuring the 
hydrodynamic size (diameter) in batch mode at 25° C in a low volume quartz cuvette 
(pathlength 10 mm). Dendrimer samples were prepared at a concentration of 2 mg/mL 
in Milli Q water and filtered through a 0.02 μm filter. A minimum of twelve 
measurements per sample were made. Hydrodynamic size is reported as the intensity-
weighted average (Z-avg). 
3.2.2.2    ZETA POTENTIAL 
Zeta potential (ζ) provides a measure of the electrostatic potential at the 
surface of the electrical double layer and the bulk medium, which is related to the 
nanoparticle surface charge. A Malvern Zetasizer Nano ZS instrument was used to 
measure zeta potential at 25° C. Dendrimer samples were prepared at a concentration 
of 2 mg/mL, respectively. An applied voltage of 100 V was used. Samples were 
loaded into pre-rinsed folded capillary cells and a minimum of three measurements 
were made per sample. 
3.2.2.3    RAMAN SPECTROSCOPY  
Indian scientists Raman and Krishnan first discovered Raman scattering effect 
in 1928. It is a spectroscopic technique based on inelastic scattering of 
monochromatic light, usually from a laser source. Inelastic scattering means that the 
photon frequency of monochromatic light changes upon interaction with a sample 
(Twardowski and Anzenbacher 1994). Samples initially absorb the laser light photons 
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followed by their reemission. Frequency of the reemitted photons is shifted up or 
down in comparison with original monochromatic frequency, which is called the 
Raman effect. This technique is capable of yielding detailed information about 
molecular vibrations. Molecular vibrations are very sensitive to strength and types of 
chemical bonds. Raman spectroscopy is useful to study solid, liquid and gaseous 
samples (Zhu, Zhu et al. 2011).  
Aqueous solutions of the purified dendrimer samples (purity ≥ 95%) (Table 1) 
were prepared to a final concentration of 1 mg/mL in water. The dendrimers aqueous 
solutions were then examined using a WITec CRM200 confocal Raman microscope. 
A diode laser of 785 nm was focused through a 20X objective of microscope. For 
measurements, solutions and solids were placed on a metal-coated slide and the 
microscope was focused on the sample. The acquisition time for all spectra was 10s. 
All Raman spectra were collected at the ambient temperature.  
3.2.2.4    SCANNING ELECTRON MICROSCOPY 
SEM uses a focused high-energy electron probe to extract structural and 
chemical information point-by-point from a region of interest in the sample. The 
spatial resolution of an SEM makes it a powerful tool to characterize a wide range of 
specimens at the nanometer to micrometer length scales. Areas ranging from 
approximately 1 cm to 5 µm in width can be imaged in a scanning mode using 
conventional SEM. The magnification ranges from 20X to 30,000X spatial resolution 
of 50-100 nm (Egerton 2005). For our studies we used Zeiss Supra 40 SEM. 
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3.2.2.5    IN VITRO TESTING OF DENDRIMERS 
3.2.2.5.1   CELL CULTURE 
HeLa and MCF-7 cells were grown in required media supplemented with 
specific amount of FBS and 1% Penicillin/Streptomycin (PAA The Cell Culture 
Company) in a humidified jacketed incubator (Binder), with a temperature of 37°C, 
5% CO2. The pH of the media was finally adjusted to pH = 7.4. The cells were 
allowed to grow to near 90% confluence before being used. Cells at passages 4-9 
were used in this study. Prior to the seeding of the cells in a 24-well plate, the cells 
were rinsed with PBS and trypsinized. The cells were seeded at a density of 1 x 105 
viable cells/mL (20 µL per well) in 24-well plates, and incubated for 24 hours prior to 
treatment with dendrimers. Controls were used. All the experiments were performed 
in triplicate (N = 3). 
3.2.2.5.2   CELL UPTAKE OF DENDRIMERS 
HeLa and MCF-7 cells were cultured for 2 days prior to use as mentioned in 
previous section of cell culture. The cells were seeded at 50,000 cells/well in a 24-
well plate and additionally incubated for 24 h prior to the dendrimer treatment. 4LL 
was used as a study drug and a control group with no treatment was used. 50 µL 
(50 µg/mL) dose of 4LL was added to each of 6 well with the remaining made up 
with 950 µL of medium with a final concentration of 1 mg/mL. In control group, 1000 
µL of medium was added to the wells. Six different time points (0-48 h) were selected 
for the study.  The uptake of the dendrimer was done using Zeiss Supra 40 SEM. 
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3.2.2.5.3    PROTOCOL FOR CELL FIXATION 
Coverslips previously coated with crosslinking agents were washed with 
HPLC grade methanol and deionized (DI) water and UV dried. Cells were grown on 
the coverslip in 24 well plate and necessary treatment (i.e. with dendrimer) was done. 
After treatment cells were washed with cold PBS and were fixed with 0.2 µm syringe-
filtered fixatives [(paraformaldehyde (4%), glutaraldehyde (0.5%)] in PBS at room 
temperature for 2 h. Fixatives were then pipetted out and cells were quenched with 
freshly prepared sodium borohydride (NaBH4) solution (1 grain + 10 ml PBS) for 10 
minutes. Quenching solution was replaced twice with each incubation time of 10 
minutes.  Cells were again washed with ice cold PBS. Removal of PBS was followed 
by wetting the surface of cells with methanol maintained at -20º C with a very brief 
contact time.  Fixed cells were then dehydrated with series of increasing concentrated 
ethanol:  30%, 70%, 80%, 90%, 95% and 100%. MCF-7 cells were maintained in 
100% ethanol until analysis. 
3.2.2.5.4    MTT CYTOTOXICITY ASSAY 
Cytotoxicity of the novel synthesized peptide (4LL, 4DL, 8LL and 8DL) was 
evaluated by widely used 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl-tetrazolium 
bromide (MTT) assay using MCF-7 cell line. MCF-7 cells were cultured in DMEM 
(Gibco, UK) supplemented with 10% heat inactivated FBS (Gibco, UK), penicillin 
and streptomycin (Sigma Aldrich, Germany). MCF-7 cells were maintained at 37ºC 
with 5% CO2 in a 95% humidity incubator. The cells were seeded in a 96-well plate in 
100 µL media per well at a density of 5,000 cells/well and incubated for 24 h. The 
media was then replaced with 100 µL of medium-containing peptides at different 
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concentrations (400, 200, 100, 50, 10, 5 and 1 µM) and incubated for 24 h. Five 
replicate wells were used for each control and peptide concentrations per microplate. 
About 100 µL MTT solution (5 mg/mL in PBS) were added to each well, followed by 
incubation at 37ºC for 4 h to allow formazan formation then the MTT were removed. 
To the resulting purple crystals, 100 µL of DMSO was added to dissolve the formazan 
crystals and incubated for 5 min at 37º C. The optical densities (OD) at 570 nm were 
determined using a microplate reader (Synergy™ H1 microplate reader, Biotek). 
Optical densities measured for well containing cells that received no peptide were 
considered to represent 100% viability (Hamidi et al. 2012; Freshney 1982).  
3.2.3   STATISTICS 
The quantitative measurement of MTT assays were expressed as mean 
percentage relative to unexposed control ± SD. Control values were set at 100%. 
Statistical analyses were carried out using the paired Student t-test in Microsoft Excel, 
where P < 0.05 was accepted as significance.  
3.3  RESULTS AND DISCUSSION  
 
3.3.1. DYNAMIC LIGHT SCATTERING (DLS) AND ZETA 
POTENTIAL (ζ) 
To understand the relationship between the particles physicochemical 
properties and the effect their size and surface charge might play on their cell uptake, 
particle size and zeta potential measurement were performed. DLS provided 
information about the hydrodynamic size (diameter) of the dendrimer in solution; this 
parameter is relevant to biological systems and is the broadly accessible method to 
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estimate the size of “soft” particles such as dendrimers (Hall et al, 2007). The zeta 
potential is the electrical potential at the surface, which separates the dendrimer in the 
solution and the molecules of the bulk solvent. Surface charge has been shown to play 
a role in dendrimer uptake.  The results of DLS and zeta potential are summarized in 
Table 3. 
Table 3. Particle hydrodynamic size was determined by DLS, shown is Z-average with 
standard deviation values (N =12). Zeta-potential as property of particle surface charge 
was performed using zetasizer (N =3).  
CODE PEPTIDE SYSTEMS Z-Avg Size DLS, nm 
Zeta Potential (ζ), 
mV 
4LL 4+ Linear L-Lys N/A 17.00 
4LLA 4+ Linear L-Lys (acid) N/A -13.50 
4LA 4+ Linear Arg N/A 15.40 
4LAA 4+ Linear Arg (acid) N/A -12.20 
4DL 4+ Lysine dendrimer N/A 14.70 
4DA 4+ Arginine dendrimer N/A 16.55 
4DH 4+ Histidine dendrimer N/A 13.19 
4DP 4+ Proline dendrimer N/A 6.36 
4DLA 4- Lysine dendrimer N/A -8.45 
8LL 8+ Linear L-Lys N/A 32.72 
8LLA 8+ Linear L-Lys (acid) N/A -35.24 
8LA 8+ Linear Arg N/A 26.15 
8LAA 8+ Linear Arg (acid) N/A -34.36 
8DP 8+ Proline dendrimer N/A 25.93 
8DA 8+ Arginine dendrimer N/A 26.30 
8DL 8+ Lysine dendrimer N/A 21.40 
 
As mentioned previously, the particle size measurement was done using 
Malvern Zetasizer Nano ZS. However, due to the small size of dendrimers, the system 
was unable to detect them at a concentration of 2 mg/mL. The zeta potential of the 
dendrimers (see table 3) however, seems to be indicative of their surface charge with 
positive zeta potential of peptide sequences ending with —NH2 (positive) terminal. 
Similarly, the sequences with —COOH (negative) terminal had negative zeta 
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potential. Further, the surface charge seems to increase with the increase in generation 
number (8 charge > 4 charge).  
3.3.2    RAMAN SPECTROSCOPY 
Raman shift is a fingerprint and contain bands, which is unique for particular 
material. Analogous to human fingerprints, Raman bands are complex and difficult to 
interpret for structural determination; however, they could be used for structural 
confirmation (Bosman, Janssen et al. 2009; Davis, Ma and Allen 2003). There are 
relatively few publications discussing the infrared spectra of dendrimers (PAMAM) 
and even fewer publications discussing Raman spectroscopic studies of dendrimers in 
general (Furer, Vandyukov et al. 2004).  It is important to understand molecules such 
as PAMAM and other dendrimers at interfaces due to their potential applications. 
More precisely, with the vast pool of prospective applications for dendritic polymers, 
understanding the intramolecular and intermolecular structure/orientation of 
dendrimers and how this orientation is impacted by the chemical and physical 
environment, i.e. at various interfaces, are significant since structure and function are 
related. This certainly requires the utilization of analytical techniques well suited to 
investigate these properties. Molecular behavior at surfaces can be quite unique and 
changes at the interface between cells and dendrimers can alter these dendrimers 
uptake (Davis, Allen et al. 2003). Further, according to one of the recent studies 
(Chang D. W. et al., 2012); dendrimers were observed to self-assemble as tubular 
structure when complexed with gold nanoparticles. So we wanted to see if our 
peptides might arrange as tubules as reported above or were similar to nanotubes, 
which may result in characteristic G, and D bands under Raman.  Further, Raman 
could represent a quantitative tool for the characterization of the dendrimers which 
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will especially be valuable in identifying how many dendrimer were taken up by the 
cells (Zhu, Zhu et al. 2011). Any such specific Raman signal for amino acid based 
peptides might help us to correlate if these signals have any impact on their functional 
properties such as dendrimer interaction with lipidic membranes and transport through 
cells (Gardikis, Hatziantoniou et al. 2006).   
Samples of 4LL, 8DL, and 8DP respectively were solubilized in water and 
spread on a glass slide. The samples were supercritical dried and analyzed.  The 
Raman signal using WITec CRM200 was collected in the spectral interval of 100 cm-1 
until 3200 cm-1, but only the region from 300 to 1600 cm-1 was used (Zhu, Zhu et al. 
2011). Experiments were performed in triplicate. Few signals were observed. 
However, no clear bands could be identified for individual dendrimers and the once 
obtained were difficult to interpret because of the similar bands as was seen with 8DP 
and 4LL (Figure 30). In figure 28, 8DP sample appeared vesicle like structures. 
Some of the vesicles were found to contract during the imaging process, which could 
be attributed to incomplete drying. The 4LL spectra (Figure 29) appeared very 
similar to that of 8DP, however, the reason behind such similarity was not apparent.  
As it can be seen in the figure 31, the overall spectra of 8DP look comparable 
to lysine, especially 4LL. Furthermore, comparison between 8DP and 4LL with that 
of 8DL shows similar profile except that the intensity of 8DL was very low. Not only 
it was not apparent as to why there was so much similarity between the two different 
dendrimers, but it was also unclear why there was a single peak difference (1600 cm-
1) between the non-black and black regions of 8DL. This necessitates further 
experiments to identify whether there was any issue in the sampling or with analysis.  










Figure 29. Raman spectra of aqueous solution of 4LL 
 








































Figure 30. Raman spectra and image of aqueous solution of 8DL. Indicated in green are 
black spot region spectra and pink are non-black region spectra. The red block indicates the 




Figure 31. Shows the superimposed spectra of various dendrimers 
 
3.3.3    CELL UPTAKE OF DENDRIMERS 
 
The MCF-7 cells were incubated with 4LL as mentioned in the previous 
section. Being a preliminary study, SEM of MCF-7 cells were done. Six different data 
points were set (0, 6, 12, 24, 36 and 48 h). However, we present the data only at 24 
and 48 h compared with control. Figure 32. a and b show MCF-7 cells with control 
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i.e. without treatment. Figure 32. c and d shows MCF-7 cells treated with 4LL at 24 h 
and e and f at 48 h. Due to the poor quality images of SEM it is difficult to conlcude 
anything. However, it will not be completely wrong to say that no visible difference is 
observed at different time points compared to the control SEM images.  
 
 
Figure 32. SEM pictures of MCF-7 cells:  (a and b) control with no treatment, (c and d) 
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3.3.4    LIVE CELL IMAGING  
In an attempt to see if we could observe the uptake of dendrimers by HeLa 
cells, we performed a preliminary experiment and observed the cells using live cell 
imaging using Zeiss live cell-imaging system. The HeLa cells were cultured for 2 
days prior to the treatment followed by their treatment with 50 µL 4LL, 8DP and 8DL 
respectively. The imaging was carried for 24 hrs. Figure 33 a, b and c below are 
representative images.  
 
 





Figure 33. Live cell image of dendrimers at 24 h a) control, b) 8DL and c) 8DP.  
Magnification 10X. The red circle indicates the area with toroid like structures. 
 As can be seen in control (without treatment) (Figure 33 a) the HeLa cells 
appear normal. In case of 8DL and 8DP (Figure 33 b and c) dendrimers, no 
significant difference was observed. However, a striking observation was the presence 
of some toroid like structures (circled in red in figure 33 b and c) found with treated 
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HeLa cells. This result corroborates with the previous study where DNA were 
complexed with dendrimers (Shah, Steptoe et al. 2011). Also no difference in terms of 
morphology of HeLa cells in case of sample and control can be interpreted as non-
toxic nature of peptide based dendrimers. However, these results need to be verified 
using tagged dendrimers.  
3.3.5   MTT CYTOTOXICITY ASSAY 
A representative of the MTT experiment assay is shown in figure 34. The 
results of cytotoxicity of dendrimers (4LL, 4DL, 8LL and 8DL) at various 
concentrations, ranging from 1 µM to 400 µM respectively, are displayed in figure 
35.  
 
Figure 34. Representative flat-bottom, 96-well plate. 
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Figure 35. Cytotoxicity of linear and branched dendrimers at various concentrations 
(ranging from 1-400 µM) on MCF-7 cells measured by MTT assay; cells were treated 
with or without dendrimers for 48 h at 37°C; Results are presented as mean ± SD, N = 5, 
when compared to the control (100% viability).  The results were significant at P < 0.05.  
As shown in figure 35, the MCF-7 cell viability after treating with 4DL was 
84% at 200 µM and decreased to 75% at 400 µM of concentration. In case of 4LL, the 
MCF-7 viability was found to be 80% at 200 µM and 70% at 400 µM, respectively, 
after 48 h of incubation.  In the series of 8 charge peptides, MCF-7 cell viability was 
lower for 8LL compared to 8DL at 200 µM (61% vs. 65% loss of viability) and 
400 µM, respectively (43% vs. 50% loss of viability). The amine-terminated 
dendrimers displayed concentration-dependent toxicity on MCF-7 cell lines. Both 4 
and 8 charge peptides seem to be biocompatible up to a concentration of 200 µM. 
However, as it has been reiterated in literature, our results also indicate that 8 charged 
peptides were more toxic compared to 4 charged peptides. This is due to the presence 
of an increasing number of exposed —NH2 terminal groups (Sebestík, Reinis et al. 
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known to possess negative charge on their surface and hence cationic dendrimers may 
show strong electrostatic interactions and consequently disturb the cell membrane and 
thus result in high cellular toxicity. Further, it can be inferred that the toxicity of our 
dendrimers is attributed to their charge over structure. 
3.4 CONCLUSIONS  
 
Amino acid based peptide dendrimers are a new class of dendrimer that has 
not been thoroughly investigated. This makes the fact interesting that there is a lot to 
explore in this area regarding their characterization and applications. In this thesis we 
attempted to investigate a few aspects such as whether specific Raman signal for 
dendrimers can be obtained as have been found with other small molecules like 
CNTs. Further SEM was used to study the cell uptake. Additionally, MTT was done 
to corroborate that the peptides were non-toxic. The first part of the thesis discussed 
the synthesis of a library of amino acid based dendrimers with different 
functionalities, including different number of end group (4 and 8), different charges 
(NH2 and COOH) and different amino acids either at the end or in between the 
sequence. This library was then purified and characterized using ESI±MS and 
analytical and preparative HPLC. In the second part of the thesis, DLS was used to 
analyze peptide samples (pH = 7.4) at a concentration of 2 mg/mL, whereby, owing to 
their small size they were undetected. Zeta potential study was conducted at a 
concentration of 2 mg/mL. As expected, the zeta potential of amine-terminated (—
NH2) peptides were positive whereas for acid terminated (—COOH) peptides it was 
negative. These values are indicative of successful surface modification of peptides. 
Furthermore, they help predict the permeation of the peptides within cells for instance 
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the amine-terminated peptides will have higher permeation compared to the acid 
peptides. Raman study of different peptide dendrimers: 4LL, 8DL and 8DP 
respectively were performed. This was an attempt to see if our amino acid based 
peptide systems will yield any specific G and D bands as it has been obtained 
previously by complexation of dendrimer with AuNPs or for CNTs (Chang D. W. et 
al., 2012) allowing for easier dendrimer characterization. Further, this information 
would have provided a quantitative evaluation on the amount of dendrimers taken up 
by cells in in vitro studies. However, no significant bands were seen and similar bands 
obtained with 4LL and 8DP. This led us to infer that may be Raman spectroscopy is 
not suitable to analyze this class of dendrimers. Next, a cell uptake study of 
dendrimers (4LL) by MCF-7 cells was performed. The samples were analyzed with 
SEM. However, due to the poor quality images obtained with SEM no conclusion can 
be drawn. But it is not completely wrong to say that no visible difference was 
observed between control and dendrimer treated samples. Similarly, live cell imaging 
was done to study the cell uptake of dendrimers. Because of the absence of any 
flourophore attachment to dendrimers, the amount of dendrimers uptake was difficult 
to be observed. However, no major difference was observed between the control and 
the treated (4LL, 8DL and 8DP respectively) groups except that there were few 
toroid-like structures observed in case of dendrimers. This was interesting because of 
the fact that a similar observation was made in one of the previous studies by our 
collaborators (Shah, Steptoe et al. 2011). Indeed, no plausible explanation behind 
such behavior is known according to our knowledge. Such an observation may be 
attributed to some protein secretions from cells, leading to a specific conformation 
(toroid like structure) of the dendrimers. Further, the peptides were tested for their 
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cytotoxicity using MTT assay. The results indicate these peptides were non-toxic even 
at concentration higher than 100 µM. As evidenced in literature, 8 charged peptides 
were found to be more toxic compared to the 4 charged peptides especially at higher 
concentration of 400 µM, for instance, 4DL vs. 8DL with 84% vs. 62% owing to their 
positive surface charge, which leads to membrane instability of cell due to 
electrostatic interaction. It can be further inferred from the MTT assay that the 
toxicity profile of these dendrimers is more dependent on their charge rather than their 
structure. Nevertheless, from this study it is reconfirmed that these low generation 
dendrimers are non-toxic in nature, which makes them a good candidate for biological 
applications.     
3.5 FUTURE PERSPECTIVES 
  
In this thesis we created a library of amino acid derived peptide dendrimers 
with different modifications and performed some preliminary experiments to be 
further characterized using conventional techniques such as ESI±MS, RP-HPLC, 
particle size and zeta potentials along with some new protocols such as Raman 
spectroscopy. In future, we will attempt to advance these dendrimers as transdermal 
drug delivery system. Future work should therefore include the following 
experiments: 
1) Study of the in vitro permeability of our dendrimers into the skin either alone or 
through ZnO nanoneedle-based device.  
2) Investigation on the effect of pH (5.5, 7.0 and 8.0, respectively) on the 
morphology of dendrimers and on their uptake in different cell lines. 
3) Conjugation of ligands or peptides to dendrimers to improve their targeted 
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delivery to diseased sites in the skin, thus more efficiently enhancing the potency 
of drugs and potentially reduce the undesired side effects. 
4) Comparison of dendrimer-based drug delivery with other nanomaterials such as 
carbon nanotubes, liposomes, micelles etc. used for drug delivery.  
5) Based on the HeLa cell uptake whereby we observed aggregate structure, the 
dendrimers will be labelled with fluorophore to track them within cells. 
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APC Antigen presenting cells 
Arg (A) Arginine 
AuNPs Gold nanoparticle 
Boc    tert-butoxycarbonyl 
CNT Carbon nanotube 
–COCH3                       Acetyl group 
–COOH Carboxy group 
DBU 1,8- diazabicyclo [5.4.0] undec-7ene 
DCM  Dichloromethane 
DETA Diethylenetriamine 
DIPC  1,3-diisopropylcarbodiimide 
DIPEA N,N-Diisopropylethylamine 
DMAP 4-(N,N-dimethylamino)pyridine 





DNA Deoxyribonucleic acid 
EGF Epidermal growth factor 
EPR Enhanced penetration and retention 
FeO Iron oxide 
Fmoc 9-fluorenylmethoxycarbonyl 
Gn Generation 
GIT Gastrointestinal tract 
Gly (G)                        Glycine 
HBTU  N-[(1H-benzotriazol-1-yl) (dimethylamino)methylene]-N-
methylmethanaminium hexafluorophosphate N-oxide 
HeLa Human cervical carcinoma  




His (H) Histidine 
ID Intradermal 
LED Light emitting diode 
Lys (L) Lysine 
MAP   Multiple antigen peptides 
MAG Multiple antigen glycopeptides 
mRNA Messenger ribonucleic acid 
MRI 
MTT 
Magnetic resonance imaging 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NaHB4 Sodium borohydride 
–NH2    Amino group 
NO Nitric oxide 
PAMAM Poly(amidoamine)  
PEG Polyethylene glycol 
PET Poly ethylene terephthalate 
PPI Poly-(propylenemine) 
Pro (P) Proline 
QD Quantum dot 





SEM Scanning electron microscopy 
siRNA Silencing ribonucleic acid 
SPPS Solid phase peptide synthesis 
TEA Triethylamine 
TEM  Transmission electron microscopy 
TFA  Trifluoroacetic acid 
TiO2 Titanium dioxide 
TIPS Triisopropylsilane 
 
